Clinical Trials Logo

Lupus Erythematosus, Discoid clinical trials

View clinical trials related to Lupus Erythematosus, Discoid.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT05362188 Completed - Clinical trials for Discoid Lupus Erythematosus

Topical Nicotinamide in Treatment of DLE

Start date: March 1, 2022
Phase: Early Phase 1
Study type: Interventional

Cutaneous lupus erythematosus (CLE) is lupus affecting the skin. In this autoimmune disease, the body's immune system attacks healthy skin. There are 3 main types: Acute cutaneous lupus, Subacute cutaneous lupus, and Chronic cutaneous lupus ("discoid lupus"). Lupus most often appears between the ages of 20 and 50 years; it affects women more than men, and it may happen more in patients with a family history of lupus or other autoimmune diseases.

NCT ID: NCT04908280 Completed - Clinical trials for Discoid Lupus Erythematosus

Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus

Start date: May 4, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the potential efficacy of topical ruxolitinib for the treatment of discoid lupus erythematosus (DLE)

NCT ID: NCT02656082 Completed - Clinical trials for Lupus Erythematosus, Cutaneous

Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus

TARGET-DLE
Start date: February 1, 2016
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether Etanercept which is given through intradermal injection is effective in the treatment of discoid lupus erythematosus (DLE). The investigators also would like to develop new tests to measure skin inflammation by scanning the affected skin using optical coherence tomography (OCT), thermography and laser doppler imaging (LDI) and taking photographs of the rash (to be done before and after treatment). If the findings from these new tests are similar to the ones from taking a sample of skin (biopsy), then the latter (which is an invasive test) can be avoided.

NCT ID: NCT02125695 Completed - Healthy Clinical Trials

Pilot Tape Harvesting Study

Start date: May 2014
Phase: N/A
Study type: Observational

The main objectives of the study are: To determine if RNA recovery from tape harvesting allows for the identification of a disease gene signature (e.g., interferon [IFN] signature for lupus) or other biomarkers that may differentiate affected from normal or unaffected skin; To determine if the lupus gene signature is differentially expressed in the epidermis from active discoid lupus erythematosus (DLE) or subacute cutaneous lupus erythematosus (SCLE) lesions when compared with unaffected skin from the same participants and from the skin of healthy volunteers (HVs); To determine if the atopic dermatitis (AD) gene signature is differentially expressed in the epidermis from active AD lesions when compared with unaffected skin from the same participants and from the skin of HVs; and To correlate the levels of transcripts of targeted genes in the skin by tape harvesting with those obtained from the blood.

NCT ID: NCT02034344 Completed - Healthy Clinical Trials

A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers

Start date: October 2013
Phase: Phase 0
Study type: Observational

The purpose of this study is to obtain skin, blood, and urine samples from patients with active cutaneous lupus lesions and from healthy participants.

NCT ID: NCT01923415 Completed - Clinical trials for Lupus Erythematosus, Systemic

A Non-drug Study Profiling Cutaneous Lupus

Start date: April 2013
Phase: Phase 0
Study type: Observational

The purpose of this study is to characterize the clinical and molecular profiles of patients with cutaneous lupus.

NCT ID: NCT01858792 Completed - Clinical trials for Lupus Erythematosus, Discoid

A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies

Start date: May 2011
Phase: N/A
Study type: Observational

Efficacy and Safety of Belimumab in a Subgroup of Systemic Lupus Erythematosus (SLE) Patients with Higher Disease Activity (anti-dsDNA positive and low complement): A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies

NCT ID: NCT01845740 Completed - Lupus Nephritis Clinical Trials

Phase Ib Study of SC Milatuzumab in SLE

Start date: January 2007
Phase: Phase 1
Study type: Interventional

Milatuzumab will be given subcutaneously at different dose levels once (depending on the dose level) for 4 weeks to determine if milatuzumab helps to control lupus (SLE).

NCT ID: NCT01597050 Completed - Clinical trials for Lupus Erythematosus, Systemic

Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions

SKINDLE
Start date: August 2012
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, efficacy and tolerability of topical R333 ointment in Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) patients with active discoid lesions.

NCT ID: NCT01300208 Completed - Clinical trials for Cutaneous Lupus Erythematosus

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Start date: October 1, 2010
Phase: Phase 2
Study type: Interventional

This is the first study in cutaneous lupus erythematosus subjects to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of CC-11050.